Medical management of metastatic prostate cancer

被引：9
|
作者：
Body, Amy [1 ]
Pranavan, Ganes [1 ,2 ]
Tan, Thean Hsiang [3 ]
Slobodian, Peter [4 ]
机构：
[1] Canberra Hosp, Dept Med Oncol, Garran, Australia
[2] Australian Natl Univ, Med Sch, Canberra, ACT, Australia
[3] Royal Adelaide Hosp, Dept Med Oncol, Adelaide, SA, Australia
[4] Royal Adelaide Hosp, Pharm, Adelaide, SA, Australia
来源：
AUSTRALIAN PRESCRIBER | 2018年 / 41卷 / 05期
关键词：
abiraterone; androgen deprivation therapy; chemotherapy; docetaxel; enzalutamide; prostate cancer; radium;
D O I：
10.18773/austprescr.2018.046
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Androgen deprivation therapy has an important role in the medical treatment of advanced and metastatic prostate cancer. The treatment of metastatic prostate cancer is influenced by whether the patient's disease has progressed on androgen deprivation therapy or not. It is considered to be castrate-resistant disease if the cancer has progressed despite adequate suppression of androgens. Chemotherapy using docetaxel or cabazitaxel and anti-androgen drugs such as abiraterone and enzalutamide can be used to treat castrate-resistant disease. Radium-223 is an option for patients with bony metastases. Metastatic castrate-resistant prostate cancer is now considered a chronic illness as the life expectancy of patients has almost doubled due to the new treatments. General practitioners are therefore more likely to encounter patients with disease- and treatment-related complications.
引用
收藏
页码：154 / 159
页数：6
相关论文
共 50 条
  • [1] Management algorithms for metastatic prostate cancer
    Malone, Shawn
    Shayegan, Bobby
    Basappa, Naveen S.
    Chi, Kim
    Conter, Henry J.
    Hamilton, Robert J.
    Hotte, Sebastien J.
    Saad, Fred
    So, Alan, I
    Park-Wyllie, Laura
    Hew, Huong
    McLeod, Deanna
    Gotto, Geoffrey
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (02): : 50 - 60
  • [2] Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions
    Gourdin, Theodore
    CURRENT OPINION IN ONCOLOGY, 2018, 30 (03) : 159 - 164
  • [3] Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem
    Alekseev, B. Ya.
    ONKOUROLOGIYA, 2015, 11 (03): : 108 - 116
  • [4] Treatment of metastatic prostate cancer in 2013
    Cathomas, R.
    Steuber, T.
    Gillessen, S.
    ONKOLOGE, 2013, 19 (09): : 756 - 761
  • [5] Systemic treatment of metastatic prostate cancer
    Lorch, Anja
    ONKOLOGE, 2017, 23 (03): : 237 - 250
  • [6] Recent Advances in the Management of Metastatic Prostate Cancer
    Kim, Soo Yeon
    Daley, Kelly
    Pruski, April D.
    AlFarra, Tariq
    Azola, Alba
    Fernandez, Marlis Gonzalez
    Keszler, Mary S.
    Friedel, Stacey
    Haaf, Hayley
    Segall, Harrison
    Lien, Peiting
    Cypher, Jacklyn
    Mazariegos, Julia
    Raghavan, Preeti
    JCO ONCOLOGY PRACTICE, 2022, 18 (01) : 53 - 60
  • [7] Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
    Gupta, Eva
    Guthrie, Troy
    Tan, Winston
    BMC UROLOGY, 2014, 14
  • [8] Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer
    Poon, Darren M. C.
    Chan, Kuen
    Chan, Tim
    Cheung, Foo-Yiu
    Lam, Daisy
    Lam, Martin
    Law, Ka-Suet
    Lee, Conrad
    Lee, Eric K. C.
    Leung, Angus
    Sze, Henry
    Tong, Chi-Chung
    Wong, Kenneth C. W.
    Kwong, Philip
    CANCERS, 2022, 14 (02)
  • [9] Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer
    Bennett, Caitlin
    Davis, Ian D.
    Hamid, Anis A.
    SEMINARS IN ONCOLOGY NURSING, 2020, 36 (04)
  • [10] The Evolving Role of Cytotoxic Chemotherapy in the Management of Patients with Metastatic Prostate Cancer
    Diamond, Elan
    del Carmen Garcias, Maria
    Karir, Beerinder
    Tagawa, Scott T.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (02)
12345